A study sponsored by Enzymotec has demonstrated that InFat provides beneficial effects for the health and well-being of formula-fed infants.
InFat, a high beta-palmitate fat blend, is a patented key product of Advanced Lipids, which is a joint venture between AAK and Enzymotec.
The double-blind, multicentre study demonstrated a considerable increase in Lactobacilli and Bifidobacteria in the microbiota, changing the intestinal flora composition to be more similar to breastfed infants.
Enzymotec infant nutrition R&D director Dr Yael Lifshitz said; "This trial indicates that InFat can significantly improve infant formula, making it closer to mother’s milk in terms of infants’ flora composition."
The study conducted at Bnai Zion Medical Center, Israel, and Meir Medical Center, Israel, was designed to assess InFat on the intestinal flora of term infants.
A total of 36 term infants, 14 breast-fed and 22 formula-fed were randomised to receive either formula with InFat or a control formula (standard vegetable oil mix) that did not contain any pre or probiotics.
The quantification of different bacteria constituting the gut flora was achieved using the stool samples collected at enrolment and at six weeks postnatal.
Advanced Lipids CEO Tzafra Cohen said; "This new publication further strengthens InFat’s leading position in the market, with numerous benefits associated with its consumption."